ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation.
Sobhy M, Eletriby A, Ragy H, Kandil H, Saleh MA, Farag N, Guindy R, Bendary A, Nayel AME, Shawky A, Khairy A, Mortada A, Zarif B, Badran H, Khorshid H, Mahmoud K, Said K, Leon K, Abdelsabour M, Tawfik M, Abdelmegid MAF, Koriem M, Loutfi M, Wadie M, Elnoamany M, Sadaka M, Seleem M, Zahran M, Amin OA, Elkaffas S, Ayad S, Kilany WE, Ammar W, Elawady W, Elhammady W, Abdelhady Y.
Sobhy M, et al.
Cardiol Ther. 2024 Dec;13(4):707-736. doi: 10.1007/s40119-024-00381-6. Epub 2024 Oct 25.
Cardiol Ther. 2024.
PMID: 39455534
Free PMC article.
Treatment with an ACEi should be started within 24 h of ST segment elevation MI (and continued long term) in patients with HF, left ventricular systolic dysfunction, and/or diabetes. ...
Treatment with an ACEi should be started within 24 h of ST segment elevation MI (and continued long term) in patients with HF, left v …